Vericel

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vericel (VCEL) reports robust Q4 earnings and eyes market expansion

Vericel (VCEL) closed 2022 with strong financial and business results, setting the stage for continued growth and profitability in 2023.
The company's focus on innovation, market expansion, and financial discipline underscores its commitment to long-term success.
Despite challenges in regulatory approvals and operational timelines, Vericel (VCEL) remains optimistic about its growth prospects and market positioning.

Vericel reports robust Q1 earnings, raises revenue guidance significantly

Vericel's Q1 performance reflects resilience and growth, with a focus on expanding revenue streams and market presence through product development and commercialization efforts.
While facing challenges in managing expenses and achieving profitability, the company's strong financial position and revenue guidance revisions signal confidence in its growth trajectory.
By capitalizing on MACI's success, navigating upcoming product launches, and maintaining financial discipline, Vericel is poised for continued success and market expansion in the regenerative medicine space.

Vericel reports robust Q2 earnings, eyes growth through new products

Vericel's strong Q2 performance and raised revenue guidance indicate a positive outlook for the company.
Challenges with NexoBrid distribution and MACI conversion rates require focused strategies for growth.
Opportunities lie in upcoming product launches and targeted sales approaches to drive revenue growth.

Vericel reports record Q3 revenue, raises guidance for 2023

Vericel's Q3 performance was exceptional, setting the stage for continued growth.
The company's strong financial position and product strategies bode well for future success.
Anticipated revenue growth in 2024 and expansion plans signal positive momentum.
Vericel aims for a robust finish in 2023 and sustained growth in 2024.

Vericel (VCEL) posts record Q4 revenue, eyes sustained growth

Vericel (VCEL) delivered robust financial results in Q4 2023, with strong revenue growth, operational efficiency, and positive market feedback on key products.
The company is well-positioned for future growth with new product launches, improved margins, and resolved customer dynamics enhancing market stability.
While challenges exist in maintaining growth momentum and managing quarterly margins, strategic investments and market opportunities offer avenues for sustained success.

Vericel (VCEL) posts stellar Q1 results, eyes market expansion

Vericel delivered a robust performance in Q1 2024, marked by revenue growth, profitability surge, and raised full-year guidance.
The company's strengths lie in margin expansion efforts, strategic investments, and plans for market expansion through new initiatives and surgeon targeting.
Challenges include balancing expenses with profitability targets and ensuring rapid adoption of new products among diverse surgeon segments.
Opportunities abound in operational efficiencies, market expansion strategies, and potential for accelerated growth based on product advantages and market positioning.

Vericel reports record Q2 revenue, eyes growth through new launches

Vericel delivered a strong performance in Q2 2024 with record revenue and profitability, driven by MACI and operational efficiency.
While facing challenges with Epicel revenue variability, the company remains optimistic about growth opportunities and market expansion.
With a focus on product launches, FDA approvals, and financial strength, Vericel is well-positioned for continued growth and success in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

First Quarter Total Net Revenue Increased 30% to $34.6 Million

Vericel Reports First Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance

CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2021 financial results and business highlights.

Vericel to Report First-Quarter 2021 Financial Results on May 5, 2021

CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 20th Annual Needham Virtual Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Thursday, April 15, 2021, at 4:30 p.m. Eastern Time.

Vericel to Present at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021

The company will be a component of a well-known small-cap stock index.

Why Vericel Stock Raced 13% Higher on Thursday

QEP Resources

NEW YORK, March 17, 2021 /PRNewswire/ -- Vericel Corp. (NASD:VCEL) will replace QEP Resources Inc. (NYSE:QEP) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, March 22. S&P 500 constituent Diamondback Energy Inc. (NASD:FANG) has acquired QEP Resources in a transaction that closed today.

Vericel Set to Join S&P SmallCap 600

In the latest trading session, Vericel Corporation (VCEL) closed at $42.92, marking a -0.26% move from the previous day.

Vericel Corporation (VCEL) Stock Sinks As Market Gains: What You Should Know

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Oppenheimer 31st Annual Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Wednesday, March 17, 2021, at 10:00 a.m. Eastern Time.

Vericel to Present at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021

Halozyme Therapeutics

Sometimes valuation metrics can be deceiving.

2 Overvalued Biotech Stocks Still Worth Buying

Vericel Corporation (VCEL) CEO Nick Colangelo on Q4 2020 Results - Earnings Call Transcript

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 19.05% and 0.40%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Vericel Corporation (VCEL) Beats Q4 Earnings and Revenue Estimates

Shares of Vericel (NASDAQ:VCEL) rose 1.0% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 25.00% year over year to $0.25, which beat the estimate of $0.20.

Recap: Vericel Q4 Earnings

CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the SVB Leerink 10th Annual Global Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Thursday, February 25, 2021, at 10:00 a.m. Eastern Time.

Vericel to Present at the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021

In the latest trading session, Vericel Corporation (VCEL) closed at $51.15, marking a -0.04% move from the previous day.

Vericel Corporation (VCEL) Dips More Than Broader Markets: What You Should Know

Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vericel Corporation (VCEL) Reports Next Week: Wall Street Expects Earnings Growth

Is (VCEL) Outperforming Other Medical Stocks This Year?

Has Vericel (VCEL) Outpaced Other Medical Stocks This Year?

CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18, 2021, at 3:00p.m. Eastern Time.

Vericel to Participate in the BTIG Virtual MedTech Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021

CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that its Board of Directors unanimously approved the termination of the Company's shareholder rights agreement, commonly referred to as a “poison pill”, which was originally scheduled to expire on August 15, 2021. The shareholder rights agreement was amended to accelerate the expiration date to February 11, 2021, effectively terminating the plan as of that date.

Vericel Announces Termination of Shareholder Rights Agreement

Vericel Corporation (VCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Vericel Corporation (VCEL) Moves to Strong Buy: Rationale Behind the Upgrade

Bull of the Day: Vericel (VCEL)

CAMBRIDGE, Mass., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, announced the appointment of Joe Mara as Chief Financial Officer of the Company, effective today.

Vericel Announces Appointment of Joe Mara as Chief Financial Officer

Record Quarterly and Full-Year Total Revenues

Vericel Announces Preliminary Fourth-Quarter and Full-Year 2020 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 23rd Annual Needham Growth Conference. The conference is being conducted in a virtual format and the presentation will take place on Friday, January 15, 2021, at 1:15 p.m. Eastern Time.

Vericel to Present at the 23rd Annual Needham Growth Conference on Friday, January 15, 2021

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that UnitedHealthcare has expanded its medical policy for MACI® (autologous cultured chondrocytes on porcine collagen membrane) to include coverage for patients with symptomatic full-thickness cartilage defects in the patella and multiple cartilage defects in the knee. UnitedHealthcare is the largest commercial payer in the United States, covering more than 26 million lives, and more patients treated with MACI are covered by UnitedHealthcare than any other plan in the United States. The revised policy is effective February 1, 2021.

Vericel Announces Expansion of MACI Coverage by UnitedHealthcare to Include Patella and Multiple Cartilage Defects in the Knee

Vericel is a high growth, disruptive biotechnology company with annual sales increasing at a 30% rate prior to the COVID-19 pandemic. The Company's tissue repair and restoration products are proprietary and backed by medical research showing greater effectiveness than traditional competing solutions and approaches.

Vericel: Biotech Leader In Engineered Tissue Solutions With Rapid Growth & Profitability

The company's earnings are expected to increase exponentially in 2021

News for Vericel Stock (VCEL)